The OncLive Insider app is live!CME Opportunities

The OncLive Insider app is live!CME Opportunities

View More Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

Breast Cancer Lung Cancer Gastrointestinal Cancer Genitourinary Cancers Ovarian Cancer Prostate Cancer Melanoma & Skin Cancer MCL MPN CAR T-cell Therapy Chronic Lymphocytic Leukemia Gynecologic Oncology Hematologic Oncology Immuno-Oncology Multiple Myeloma Urothelial Cancer

All Oncology News

OncLive News Network®

Insights MedNews Week OncChats OncLive News Network®OncLive TV Peer Exchange Podcasts Rapid Readouts

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Giants of Cancer Care

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Giants of Cancer Care CME/CE Scientific Interchanges State of the Science Summit / IPC National Fellows Forum Webinars

Partners Publications

Consensus Viewpoints

Interactive Tools

Consensus Viewpoints OncLive App Interactive Tools Sponsored

Biomarker Consortium Subscribe

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

© 2025 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

The OncLive Insider app is live!
CME Opportunities

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

OncLive SOSS

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.

The Emerging Role of FLT3 Inhibitors in AML and ASM

EP. 1: Genetic Complexities in AML

December 1st 2016

EP. 2: AML: Induction Therapy and Minimal Residual Disease

December 1st 2016

EP. 3: Post Remission Decisions in AML

December 1st 2016

EP. 4: FLT3 Mutation Status in AML

December 1st 2016

EP. 5: The Rationale of FLT3 Inhibition in AML

December 1st 2016

EP. 6: AML: The RATIFY Clinical Trial

December 1st 2016

EP. 7: The Efficacy of Midostaurin in Subsets of AML

December 1st 2016

EP. 8: Emerging Targeted Agents in AML

December 1st 2016

EP. 9: Subtypes and Characteristics of Mastocytosis

December 1st 2016

EP. 10: Advanced SM: Diagnosis and Initial Treatment Approach

December 1st 2016

<
1
2
>

x